GCG and type 2 diabetes mellitus: Only 1.2% of the prescriptions for incretin-based pharmacotherapy generated by the health system described in this analysis over the timeframe of interest were for patients meeting the inclusion criteria of a diagnosis of T2DM and a baseline BMI of <25 kg/m2, despite the fact that the CDC reports about 10% of patients with T2DM are classified as normal weight or underweight [2].